MilliporeSigma
  • Home
  • Search Results
  • Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein.

Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein.

Oncogene (2006-06-27)
G Yang, M A Thompson, S J Brandt, S W Hiebert
ABSTRACT

The t(8;21) chromosomal translocation that generates the fusion oncoprotein RUNX1-ETO predominates in leukemia patients of the French-American-British (FAB) class M2 subtype. The oncoprotein has the capacity to promote expansion of hematopoietic stem/progenitor cells and induces leukemia in association with other genetic alterations. Here, we show that RUNX1-ETO undergoes degradation in response to treatment with histone deacetylase inhibitors, one of which, depsipeptide (DEP), is currently undergoing phase II clinical testing in a variety of malignancies. These compounds induce turnover of RUNX1-ETO without affecting the stability of RUNX1-ETO partner proteins. In addition, RUNX1-ETO physically interacts with heat shock protein 90 (HSP90). DEP treatment interrupts the association of RUNX1-ETO with HSP90 and induces proteasomal degradation of RUNX1-ETO. DEP and the HSP90 antagonist 17-allylamino-geldanamycin (17-AAG) both triggered RUNX1-ETO degradation, but without any additive or cooperative effects. These findings may stimulate the development of more rational and effective approaches for treating t(8;21) patients using histone deacetylase inhibitors or HSP90 inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-acetyl-Lysine Antibody, serum, Upstate®
Millipore
Protein G Sepharose®, Fast Flow, recombinant, expressed in E. coli, aqueous ethanol suspension
Sigma-Aldrich
Goat Anti-Rabbit IgG Antibody, (H+L) HRP conjugate, 1 mg/mL, Chemicon®